Cabozantinib Shows Encouraging Activity in Metastatic Castrate‑resistant Prostate Cancer The ASCO Post, 16 Dec 2013
Cervical Cancer Screening Study Should Reassure Physicians and Patients that a 3-Year Screening Interval Is Safe and Effective The ASCO Post, 16 Dec 2013